STOCK TITAN
  1. Home
  2. News
  3. CAPR

Capricor Therapeutics Inc - CAPR STOCK NEWS

Welcome to our dedicated news page for Capricor Therapeutics (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Capricor Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Capricor Therapeutics's position in the market.

News
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Rhea-AI Summary
Capricor Therapeutics announces positive outcomes from a Type-B meeting with the FDA regarding the CAP-1002 program for Duchenne Muscular Dystrophy. The FDA supports requests for a Pre-BLA meeting and Rolling BLA submission, aligning with the company on non-clinical comparability. Capricor plans to share 3-year safety and efficacy data with the FDA in the second quarter of 2024. The company is on track to potentially accelerate the BLA filing process for CAP-1002 treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
-
News
Capricor Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Capricor Therapeutics (CAPR) to present at H.C. Wainwright and Cantor Fitzgerald conferences to discuss progress on CAP-1002 for Duchenne muscular dystrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
-
News
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Rhea-AI Summary
Capricor Therapeutics (CAPR) announces positive 24-month results from HOPE-2 open-label extension study of CAP-1002 in Duchenne Muscular Dystrophy. The study shows significant improvements in skeletal and cardiac muscle function, with a 64% reduction in disease progression. CAP-1002 demonstrates a favorable safety profile and potential long-term benefits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
none
News
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Capricor Therapeutics announces completion of enrollment in Cohort A of Phase 3 trial for CAP-1002 in Duchenne Muscular Dystrophy, successful interim analysis, and plans for top-line data reporting in Q4 2024. The company also discloses upcoming FDA meeting for commercial manufacturing planning, expansion at San Diego facility, and 3-year data report in Q2 2024. Additionally, Capricor shares updates on a clinical trial collaboration with NIH, financial results, and corporate milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.69%
Tags
earnings
-
News
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Rhea-AI Summary
Capricor Therapeutics (CAPR) has secured an in-person Type-B meeting with the FDA to discuss its chemistry, manufacturing, and controls (CMC) plans for commercial launch, potentially expediting the Biologics License Application (BLA) submission. The company holds RMAT and orphan drug designations for CAP-1002 in Duchenne muscular dystrophy, aiming to accelerate approval pathways. With the Phase 3 HOPE-3 trial fully enrolled, Capricor is focused on swift approval and patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.6%
Tags
none
-
News
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
Rhea-AI Summary
Capricor Therapeutics (CAPR) will host a conference call on February 29, 2024, to discuss its financial results for the fourth quarter and full year ended December 31, 2023. The company focuses on developing cell and exosome-based therapeutics for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences earnings
News
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Rhea-AI Summary
Capricor Therapeutics (CAPR) announces manufacturing scale-up for CAP-1002 and rapid enrollment in Phase 3 clinical trial. The company aims for commercial use with a new facility in San Diego and plans to discuss expedited approval with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
none
-
News
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) announced that its proprietary StealthX™ exosome-based multivalent vaccine for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases will conduct a Phase 1 clinical study with Capricor’s vaccine, subject to regulatory approval. The vaccine is designed to deliver both the highly mutagenic S protein and the more stable N protein, potentially offering broader and longer-lasting immunity against SARS-CoV-2. The vaccine is free of both adjuvant and lipid nanoparticles and has generated a strong immune response at low doses in preclinical studies. This collaboration provides non-dilutive support for the advancement of Capricor’s vaccine candidate and highlights the clinical potential of the company's exosome platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
clinical trial
-
News
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
Rhea-AI Summary
Capricor Therapeutics (CAPR) announces favorable interim futility analysis results for HOPE-3 trial evaluating CAP-1002 in patients with Duchenne muscular dystrophy. Successful completion triggers first milestone payment under U.S. agreement with Nippon Shinyaku. Enrollment complete for Cohort A with topline data expected in Q4 2024; Cohort B enrollment initiated. Plans to request FDA meeting in Q1 2024 for expedited approval pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
clinical trial
News
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) completes targeted enrollment for HOPE-3, Phase 3 trial of CAP-1002 in Duchenne Muscular Dystrophy. On track to report interim futility analysis in Q4 2023; Successful outcome triggers milestone payment. Positive FDA feedback confirms CAP-1002’s path towards Biologics License Application. Corporate update includes financial results, operational developments, and anticipated milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
earnings
Stock CAPR logo
Capricor Therapeutics Inc

Nasdaq:CAPR

CAPR Rankings

#3918 Ranked by Market Cap
#4693 Ranked by Stock Gains
N/A Ranked by Dividends

CAPR Stock Data

196.89M
26.04M
8.2%
21.62%
11.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Beverly Hills

About CAPR

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has